ArticleJournal of geriatric cardiology : JGC2022
Fulminant myocarditis in adults: a narrative review.
Article in Journal of geriatric cardiology : JGC, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 21 citations in OpenAlex.
- Article
- Early temporary ventricular assist device intervention improves survival in fulminant myocarditis with cardiogenic shock: experience from a single centre and national cohort.Frontiers in cardiovascular medicine · 2026Article
- Fulminant Myocarditis With Normal Inflammatory Markers.JACC. Case reports · 2025Article
- Fulminant Influenza Myocarditis Requiring Extracorporeal Membrane Oxygenation (ECMO) Support.Cureus · 2025Article
- Review
- Article
- Comparison of predictors of survival among fulminant myocarditis patients undergoing veno-arterial extracorporeal membrane oxygenation in the adult and pediatric populations.Annals of medicine and surgery (2012) · 2024Article
- Pyruvate kinase M2 sustains cardiac mitochondrial quality surveillance in septic cardiomyopathy by regulating prohibitin 2 abundance via S91 phosphorylation.Cellular and molecular life sciences : CMLS · 2024Article
- Clinical Application of Extracorporeal Membrane Oxygenation in the Treatment of Fulminant Myocarditis.Reviews in cardiovascular medicine · 2024Review
- Mechanical Circulatory Support Systems in Fulminant Myocarditis: Recent Advances and Outlook.Journal of clinical medicine · 2024Review
- Dual-specificity phosphatase 1 interacts with prohibitin 2 to improve mitochondrial quality control against type-3 cardiorenal syndrome.International journal of medical sciences · 2024Article
- Altered Gut Microbiota as a Potential Risk Factor for Coronary Artery Disease in Diabetes: A Two-Sample Bi-Directional Mendelian Randomization Study.International journal of medical sciences · 2024Article
- Advances in myocarditis management in the light of the latest research and recent guidelines of the European Society of Cardiology.Cardiology journal · 2024Review
- The Epidemiology of COVID-19 Vaccine-Induced Myocarditis.Advances in medicine · 2024Review
- METTL3 boosts mitochondrial fission and induces cardiac fibrosis after ischemia/reperfusion injury.International journal of biological sciences · 2024Article
- Involvement of mitochondrial dynamics and mitophagy in diabetic endothelial dysfunction and cardiac microvascular injury.Archives of toxicology · 2023Review
- Update on Myocarditis: From Etiology and Clinical Picture to Modern Diagnostics and Methods of Treatment.Diagnostics (Basel, Switzerland) · 2023Review
- Immunopathogenesis and immunomodulatory therapy for myocarditis.Science China. Life sciences · 2023Review
- A case of fulminant myocarditis with full recovery after a 38-h sustained asystole.Clinical case reports · 2023Article
- The role of temporary mechanical circulatory support inJournal of intensive medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fulminant myocarditis (FM) is an uncommon syndrome characterized by sudden and severe hemodynamic compromise secondary to acute myocardial inflammation, often presenting as profound cardiogenic shock, life-threatening ventricular arrhythmias and/or electrical storm. FM may be refractory to conventional therapies and require mechanical circulatory support (MCS). The immune system has been recognized as playing a pivotal role in the pathophysiology of myocarditis, leading to an increased focus on immunosuppressive treatment strategies. Recent data have highlighted not only the fact that FM has significantly worse outcomes than non-FM, but that prognosis and management strategies of FM are heavily dependent on histological subtype, placing greater emphasis on the role of endomyocardial biopsy in diagnosis. The impact of subtype on severity and prognosis will likewise influence how aggressively the myocarditis is managed, including whether MCS is warranted. Many patients with refractory cardiogenic shock secondary to FM end up requiring MCS, with venoarterial extracorporeal membrane oxygenation demonstrating favorable survival rates, particularly when initiated prior to the development of multiorgan failure. Among the challenges facing the field are the need to more precisely identify immunopathophysiological pathways in order to develop targeted therapies, and the need to better optimize the timing and management of MCS to minimize complications and maximize outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.